KEYNOTE355 Randomized DoubleBlind Phase 3 Study of Pembrolizumab

KEYNOTE-355: Randomized, Double-Blind, Phase 3 Study of Pembrolizumab + Chemotherapy versus Placebo + Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer Presented By Javier Cortes at TBD

Pembrolizumab Monotherapy in m. TNBC Presented By Javier Cortes at TBD

Pembrolizumab Plus Chemotherapy Presented By Javier Cortes at TBD

KEYNOTE-355 Study Design (NCT 02819518) Presented By Javier Cortes at TBD

Study Endpoints Presented By Javier Cortes at TBD

Statistical Considerations Presented By Javier Cortes at TBD

Treatment Disposition of All Randomized Patients Presented By Javier Cortes at TBD

Baseline Characteristics, ITT Presented By Javier Cortes at TBD

Progression-Free Survival: PD-L 1 CPS ≥ 10 Presented By Javier Cortes at TBD

Progression-Free Survival: PD-L 1 CPS ≥ 10 Presented By Javier Cortes at TBD

Progression-Free Survival: PD-L 1 CPS ≥ 1 Presented By Javier Cortes at TBD

Progression-Free Survival: ITT Presented By Javier Cortes at TBD

Progression-Free Survival in PD-L 1 CPS Subgroups Presented By Javier Cortes at TBD

Progression-Free Survival in Subgroups: PD-L 1 CPS ≥ 10 Presented By Javier Cortes at TBD

Progression-Free Survival in Subgroups: PD-L 1 CPS ≥ 1 Presented By Javier Cortes at TBD

Progression-Free Survival in Subgroups: ITT Presented By Javier Cortes at TBD

Treatment-Related AEs Presented By Javier Cortes at TBD

Immune-Mediated AEs Presented By Javier Cortes at TBD

Summary Presented By Javier Cortes at TBD

Acknowledgements Presented By Javier Cortes at TBD